Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. SBC
SBC logo

SBC Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
3.080
Open
2.990
VWAP
2.94
Vol
86.61K
Mkt Cap
294.40M
Low
2.870
Amount
254.63K
EV/EBITDA(TTM)
2.86
Total Shares
102.58M
EV
182.47M
EV/OCF(TTM)
5.71
P/S(TTM)
1.74
SBC Medical Group Holdings Incorporated is a management company, which owns, operates, and provides management services to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including, but not limited to, advertising and marketing needs across various platforms, staff management, booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumable's procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic’s customer rewards program, and payment tools for the franchisee clinics.
Show More

Events Timeline

(ET)
2026-05-14
06:40:00
SBC Medical Reports Q1 Revenue of $43M, Below Expectations
select
2026-03-27 (ET)
2026-03-27
16:30:00
Major Averages Drop Due to Strait of Hormuz Incidents
select
2026-03-27
12:00:00
Major Averages Decline Amid Middle East Tensions
select
2026-03-27
06:50:00
SBC Medical Reports 11% Increase in Average Revenue per Customer in Q4
select
2026-03-27
06:50:00
SBC Medical Q4 Revenue at $40M, Below Consensus
select
2026-03-24 (ET)
2026-03-24
08:20:00
SBC Medical Group Launches SBC Wellness 2.0 Platform
select

News

Fool
7.5
06-05Fool
Visa Partners with Brale to Explore Stablecoin Settlement
  • Stablecoin Settlement Collaboration: Visa announced a partnership with Brale to explore settlement using its developed stablecoin, aiming to conduct a proof of concept through the Canton Network, which, if successful, could integrate stablecoin into Visa's settlement currency network, enhancing transaction speed and privacy.
  • Positive Market Reaction: This news led to a more than 2% increase in Visa's stock price, significantly outperforming the S&P 500's 0.4% rise, indicating investor optimism regarding Visa's proactive involvement in next-generation financial solutions.
  • Efficiency in Transactions: By clearing transactions instantly on the blockchain, Visa can drastically reduce idle capital and improve fund utilization, further solidifying its position as a leading payment card brand in the market.
  • Future Growth Potential: Visa's stablecoin initiative aligns with its reported participation in a new stablecoin consortium, showcasing the company's forward-looking strategy in emerging financial solutions, which enhances confidence in its future profitability.
NASDAQ.COM
7.5
06-05NASDAQ.COM
Visa Partners with Stable Coin to Explore Settlement Solutions
  • Stablecoin Settlement Pilot: Visa is collaborating with Brale, the developer of Stable Coin, to conduct a proof of concept for stablecoin settlements via the Canton Network, which, if successful, could significantly enhance transaction efficiency and reduce idle capital.
  • Positive Market Reaction: The announcement led to a more than 2% increase in Visa's stock price, easily surpassing the S&P 500's 0.4% rise, indicating strong investor confidence in the company's future potential.
  • Blockchain Technology Application: Cuy Sheffield, Visa's head of crypto, noted that stablecoin settlements demonstrate how blockchain infrastructure can improve the speed and efficiency of money movement, potentially transforming traditional banking's slow processing methods.
  • Optimistic Industry Outlook: Visa's involvement in a stablecoin consortium highlights its commitment to next-generation financial solutions, further solidifying its leadership position in the payments industry and potentially providing long-term strategic advantages.
Newsfilter
1.0
05-26Newsfilter
SBC Medical Group to Participate in Investor Conferences
  • Investor Conference Schedule: SBC Medical Group will participate in several investor conferences in May and June 2026, including Lytham Partners and Noble Capital Markets, aiming to enhance its visibility and credibility among institutional investors through webcasts and one-on-one meetings.
  • Meeting Dates and Formats: The company plans to hold one-on-one meetings on May 28 and deliver a webcast presentation at the Noble Capital Markets conference on June 3, showcasing its innovations and developments in the healthcare sector, which is expected to attract more investor interest in its growth potential.
  • Global Expansion Strategy: SBC Medical Group is focused on expanding its global presence in the U.S. and Asia through direct operations and medical tourism initiatives, covering various fields such as aesthetic healthcare, dermatology, and orthopedics, thereby enhancing its market competitiveness and brand influence.
  • NASDAQ Listing Background: Since its listing on NASDAQ in September 2024, SBC Medical Group was included in the Russell 3000® Index in June 2025, marking an increase in its recognition in the U.S. equity market, which is anticipated to provide more opportunities for future financing and market expansion.
Newsfilter
7.5
05-22Newsfilter
SBC Medical Opens New Dermatology Section in Thailand
  • New Business Launch: SBC Medical, in partnership with BLEZ ASIA, inaugurates a new aesthetic dermatology section at BLEZ CLINIC in Bangkok's Asok district, with services set to commence in June 2026, marking a significant milestone in the company's Thai market efforts.
  • Market Opportunity: With Thailand's aesthetic healthcare market experiencing rapid growth, SBC Medical aims to leverage its collaboration with BLEZ ASIA to meet the high-quality service demands of Japanese expatriates, thereby enhancing its competitive position.
  • Service Features: The new dermatology section will focus on pico laser treatments for pigmentation and spot removal, ensuring a safe and professional medical environment for Japanese expatriates, which is crucial for building customer trust.
  • Strategic Expansion Plan: Following the establishment of a strong reputation in Asok, SBC Medical plans to gradually expand into the broader Thai market and across ASEAN, committed to delivering high-quality medical services that cater to local needs and create new market value.
seekingalpha
9.5
05-14seekingalpha
SBC Medical Group Q1 2026 Earnings Call Insights
  • Revenue Decline Analysis: Total revenues for Q1 2026 were $43 million, reflecting a 9% year-over-year decline primarily due to fee structure revisions implemented in April last year, which negatively impacted franchising revenue by $6.2 million and management services revenue by $2.4 million, totaling an $8.7 million decrease, indicating challenges in revenue structure adjustments.
  • Profitability Decline: Net income decreased year-over-year, partly due to a one-time life insurance gain of $8.7 million in the prior year; however, excluding the impact of fee structure revisions, underlying revenue grew by 11% year-over-year, demonstrating potential business resilience.
  • AI Strategy Advancement: The company is promoting an AI initiative aimed at driving top-line growth through enhanced customer experiences while also enabling a leaner, more efficient organization, with management expressing optimism about future growth as the impact of fee structure adjustments rolls off.
  • Cash Flow and Investment Priorities: Management emphasized that while the current share repurchase program is not a priority, the company has a strong cash position and plans to prioritize growth investments, particularly in seeking M&A opportunities within the competitive Japanese aesthetic market.
seekingalpha
9.5
05-14seekingalpha
SBC Medical Group Q1 Earnings Report
  • Earnings Highlights: SBC Medical Group reported a Q1 GAAP EPS of $0.11, reflecting resilience in the current market despite a 9.1% year-over-year decline, indicating ongoing profitability amidst challenges.
  • Revenue Performance: The company generated $43 million in revenue for Q1, down 9.1% year-over-year and missing market expectations by $5.87 million, highlighting challenges in revenue growth that could impact investor confidence moving forward.
  • Secondary Offering Announcement: SBC Medical announced a secondary offering of 3.1 million shares by a selling stockholder, aimed at strengthening its capital structure and providing funding for future expansion, demonstrating a proactive approach to market opportunities.
  • Analyst Ratings: While the Q1 GAAP EPS of $0.14 beat expectations by $0.03, the revenue of $39.57 million fell short of projections, reflecting a cautious market sentiment regarding the company's future performance and potential stock price implications.
Wall Street analysts forecast SBC stock price to rise
1 Analyst Rating
Wall Street analysts forecast SBC stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
9.00
Averages
9.00
High
9.00
Current: 0.000
sliders
Low
9.00
Averages
9.00
High
9.00
BTIG
Sam Eiber
initiated
$8
AI Analysis
2026-03-06
Reason
BTIG
Sam Eiber
Price Target
$8
AI Analysis
2026-03-06
initiated
Reason
BTIG analyst Sam Eiber initiated coverage of SBC Medical Group with a Buy rating and $8 price target. SBC is the leading aesthetic medical group in Japan with more than 250 franchises and over 6.5M annual patient visits, the analyst tells investors in a research note. The firm says the shares represent an opportunity for investors looking to own an outside of the U.S. business that has "numerous growth prospects" and is trading at a discount to peers.
Maxim
Maxim
initiated
$9
2025-11-05
Reason
Maxim
Maxim
Price Target
$9
2025-11-05
initiated
Reason
Maxim initiated coverage of SBC Medical Group with a Buy rating and $9 price target.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for SBC
Unlock Now

Valuation Metrics

The current forward P/E ratio for SBC Medical Group Holdings Inc (SBC.O) is 6.45, compared to its 5-year average forward P/E of 4.35. For a more detailed relative valuation and DCF analysis to assess SBC Medical Group Holdings Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
4.35
Current PE
6.45
Overvalued PE
8.38
Undervalued PE
0.31

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.76
Current EV/EBITDA
1.92
Overvalued EV/EBITDA
2.22
Undervalued EV/EBITDA
-0.71

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.28
Current PS
1.56
Overvalued PS
2.43
Undervalued PS
0.13

Financials

AI Analysis
Annual
Quarterly

Whales Holding SBC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is SBC Medical Group Holdings Inc (SBC) stock price today?

The current price of SBC is 2.87 USD — it has decreased -4.01

What is SBC Medical Group Holdings Inc (SBC)'s business?

SBC Medical Group Holdings Incorporated is a management company, which owns, operates, and provides management services to cosmetic treatment centers. The Company is primarily focused on providing comprehensive management services to franchisee clinics, including, but not limited to, advertising and marketing needs across various platforms, staff management, booking reservations for franchisee clinic customers, assistance with franchisee employee housing rentals and facility rentals, construction and design of franchisee clinics, medical equipment and medical consumable's procurement (resale), the provision of cosmetic products to franchisee clinics for resale to clinic customers, licensure of the use of patent-pending and non-patented medical technologies, trademark and brand use, IT software solutions (including but not limited to remote medical consultations), management of the franchisee clinic’s customer rewards program, and payment tools for the franchisee clinics.

What is the price predicton of SBC Stock?

Wall Street analysts forecast SBC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SBC is9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is SBC Medical Group Holdings Inc (SBC)'s revenue for the last quarter?

SBC Medical Group Holdings Inc revenue for the last quarter amounts to 43.06M USD, decreased -9.02

What is SBC Medical Group Holdings Inc (SBC)'s earnings per share (EPS) for the last quarter?

SBC Medical Group Holdings Inc. EPS for the last quarter amounts to 0.11 USD, decreased -47.62

How many employees does SBC Medical Group Holdings Inc (SBC). have?

SBC Medical Group Holdings Inc (SBC) has 863 emplpoyees as of June 15 2026.

What is SBC Medical Group Holdings Inc (SBC) market cap?

Today SBC has the market capitalization of 294.40M USD.